Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ. Taal W, et al. Among authors: buter j. Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15. Lancet Oncol. 2014. PMID: 25035291 Clinical Trial.
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B, Smits M. Gahrmann R, et al. Among authors: buter j. Neuro Oncol. 2017 Jun 1;19(6):853-861. doi: 10.1093/neuonc/now311. Neuro Oncol. 2017. PMID: 28204639 Free PMC article. Clinical Trial.
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ. Erdem-Eraslan L, et al. Among authors: buter j. Cancer Res. 2016 Feb 1;76(3):525-34. doi: 10.1158/0008-5472.CAN-15-0776. Epub 2016 Jan 13. Cancer Res. 2016. PMID: 26762204 Clinical Trial.
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis.
Hoogstrate Y, Ghisai SA, de Wit M, de Heer I, Draaisma K, van Riet J, van de Werken HJG, Bours V, Buter J, Vanden Bempt I, Eoli M, Franceschi E, Frenel JS, Gorlia T, Hanse MC, Hoeben A, Kerkhof M, Kros JM, Leenstra S, Lombardi G, Lukacova S, Robe PA, Sepulveda JM, Taal W, Taphoorn M, Vernhout RM, Walenkamp AME, Watts C, Weller M, de Vos FYF, Jenster GW, van den Bent M, French PJ. Hoogstrate Y, et al. Among authors: buter j. Neuro Oncol. 2022 Mar 12;24(3):429-441. doi: 10.1093/neuonc/noab231. Neuro Oncol. 2022. PMID: 34608482 Free PMC article.
The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.
Gahrmann R, Smits M, Vernhout RM, Taal W, Kapsas G, de Groot JC, Hanse M, Vos M, Beerepoot LV, Buter J, Flach ZH, van der Holt B, van den Bent M. Gahrmann R, et al. Among authors: buter j. Neurooncol Adv. 2022 Mar 9;4(1):vdac032. doi: 10.1093/noajnl/vdac032. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35419519 Free PMC article.
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group. Mehanna H, et al. Among authors: buter j. Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15. Lancet. 2019. PMID: 30449623 Free PMC article. Clinical Trial.
103 results